FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced it has been granted Food and Drug Administration conditional Investigational Device Exemption approval to evaluate the safety and effectiveness of its CorPath?® 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary interventions procedures.

"Improving precision of PCI procedures and the ergonomic conditions of the cath lab will ultimately improve patient procedures," said Joseph P. Carrozza, Jr. M.D., co-principal investigator and Chief of Cardiovascular Medicine at St. Elizabeth’s Medical Center in Boston. "The CorPath System allows interventional cardiologists to operate in a comfortable environment, completely focused on the patient’s physiology. The ergonomically optimized cockpit enhances visualization, while minimizing fatigue, radiation exposure and other occupational hazards, such as back strain."

The CorPath PRECISE (Percutaneous Robotic-Enhanced Coronary Intervention Study) trial will be conducted at leading medical centers across the United States, including Columbia University Medical Center in New York, St. Elizabeth’s Medical Center in Boston, Virginia Commonwealth University Medical Center in Richmond, Va., and St. Joseph’s Hospital Health Center in Syracuse, New York. The results of this study will be the basis for a Pre-market clearance (510(k)) application to the FDA.

"The initiation of the CorPath PRECISE trial is a tremendous milestone for Corindus," said David M. Handler, President and CEO of Corindus. "We believe the CorPath System has the potential to raise the standard of care in PCI by cost effectively improving procedure results, while ultimately extending the physician’s capability, and career."

The first procedures in the trial are targeted for early 2011. Previously, Corindus Vascular Robotics completed its first-in-human clinical trial with CorPath 200 System in March 2010. These results met the company’s safety and efficacy endpoints and were among the data the FDA considered in granting conditional IDE approval.

Source: Corindus

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s